Inspire Medical Systems (INSP) shares plunged 5.86% in pre-market trading on Tuesday, February 11, 2025, after multiple analysts lowered their price targets on the stock.
Truist Securities cut its price target on INSP to $235 from $250, though it maintained a Buy rating on the medical device company. Meanwhile, Wells Fargo also reduced its price target on INSP to $195 from $198.
The downward revisions in analysts' price targets appear to be the primary reason behind INSP's pre-market sell-off, as investors reacted negatively to the lowered expectations for the stock's future performance.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。